"10.1371_journal.pone.0075091","plos one","2013-09-20T00:00:00Z","Johanna Gaiottino; Niklas Norgren; Ruth Dobson; Joanne Topping; Ahuva Nissim; Andrea Malaspina; Jonathan P Bestwick; Andreas U Monsch; Axel Regeniter; Raija L Lindberg; Ludwig Kappos; David Leppert; Axel Petzold; Gavin Giovannoni; Jens Kuhle","Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; Bone & Joint Research Unit, John Vane Science Centre, Queen Mary University of London, London, United Kingdom; UmanDiagnostics, Umeå, Sweden; North-East London and Essex Regional MND Care Centre, London, United Kingdom; Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; Memory Clinic, Department of Geriatrics, University Hospital, Basel, Basel, Switzerland; Laboratory Medicine, University Hospital, Basel, Basel, Switzerland; Department of Neurology, University Hospital, Basel, Basel, Switzerland; UCL Institute of Neurology, Department of Neuroinflammation, London, United Kingdom","Conceived and designed the experiments: JG NN AN AM JPB AP GG JK. Performed the experiments: JG JK. Analyzed the data: JG NN RD AN AM JPB DL AP JK. Contributed reagents/materials/analysis tools: JG NN RD JT AN AM AUM AR AP GG JK. Wrote the manuscript: JG NN RD JT AN AM JPB AUM AR RLL LK DL AP GG JK.","J. Gaiottino reports no disclosures; N. Norgren is employed by UmanDiagnostics AB, Sweden; R. Dobson, J. Topping, A. Nissim, A. Malsapina, J.P. Bestwick, A.U. Monsch, A. Regeniter report no disclosures; R.L. Lindberg has received research support from the Swiss MS Society, Swiss National Science Foundation, European FP6 and IMI JU programs, Roche Postdoc Fellowship Program (RPF-program), unrestricted research grants from Novartis and Biogen. L. Kappos reports, the University Hospital Basel as employer of Dr. Kappos has received and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Actelion, Advancell, Allozyne, Bayer, Bayhill, Biogen Idec, BioMarin, CSL Behring, Eli Lilly, European Union, GeNeuro, Genmab, Gianni Rubatto Foundation, Glenmark, Merck Serono, MediciNova, Mitsubishi Pharma, Novartis, Novartis Research Foundation, Novonordisk, Peptimmune, Roche, Roche Research Foundation, Sanofi-Aventis, Santhera, Swiss MS Society, Swiss National Research Foundation, Teva, UCB, and Wyeth. D. Leppert is an employee of F. Hoffmann-La Roche Ltd. A. Petzold reports no disclosure. G. Giovannoni has received research grant support from Bayer–Schering Healthcare, Biogen–Idec, GW Pharma, Merck Serono, Merz, Novartis, Teva and Sanofi–Aventis. He has received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Bayer–Schering Healthcare, Biogen–Idec, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, Ironwood, Merck–Serono, Novartis, Pfizer, Roche, Sanofi–Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals. J. Kuhle has received research support from the Swiss MS Society, Swiss ALS Society, Protagen AG, Roche and Novartis and served in scientific advisory boards for Genzyme/Sanofi-Aventis, Merck Serono and Novartis Pharma. His work is supported by an ECTRIMS Research Fellowship Programme and by the “Forschungsfonds” of the University of Basel, Switzerland. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","09","Johanna Gaiottino","JG",15,TRUE,8,2,9,15,TRUE,TRUE,FALSE,0,NA,FALSE
